The psoriatic arthritis therapeutics drugs market is witnessing strong growth driven by increasing prevalence, advancements in biologics, and rising adoption of targeted therapies. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Psoriatic Arthritis Therapeutics Drugs Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Psoriatic Arthritis Therapeutics Drugs Market Revenue and Volume Forecast, by Drug Class
8.1.1. Conventional DMARDs (cDMARDs)
8.1.1.1. Market Revenue and Volume Forecast
8.1.2. Biologics
8.1.2.1. Market Revenue and Volume Forecast
8.1.3. Targeted Synthetic DMARDs (tsDMARDs)
8.1.3.1. Market Revenue and Volume Forecast
8.1.4. Others
8.1.4.1. Market Revenue and Volume Forecast
9.1. Psoriatic Arthritis Therapeutics Drugs Market Revenue and Volume Forecast, by Route of Administration
9.1.1. Oral
9.1.1.1. Market Revenue and Volume Forecast
9.1.2. Injectable
9.1.2.1. Market Revenue and Volume Forecast
10.1. Psoriatic Arthritis Therapeutics Drugs Market Revenue and Volume Forecast, by Patient Type
10.1.1. Adult
10.1.1.1. Market Revenue and Volume Forecast
10.1.2. Pediatric
10.1.2.1. Market Revenue and Volume Forecast
11.1. Psoriatic Arthritis Therapeutics Drugs Market Revenue and Volume Forecast, by Distribution Channel
11.1.1. Hospital Pharmacies
11.1.1.1. Market Revenue and Volume Forecast
11.1.2. Retail Pharmacies
11.1.2.1. Market Revenue and Volume Forecast
11.1.3. Online Pharmacies
11.1.3.1. Market Revenue and Volume Forecast
12.1. North America
12.1.1. Market Revenue and Volume Forecast, by Drug Class
12.1.2. Market Revenue and Volume Forecast, by Route of Administration
12.1.3. Market Revenue and Volume Forecast, by Patient Type
12.1.4. Market Revenue and Volume Forecast, by Distribution Channel
12.1.5. U.S.
12.1.5.1. Market Revenue and Volume Forecast, by Drug Class
12.1.5.2. Market Revenue and Volume Forecast, by Route of Administration
12.1.5.3. Market Revenue and Volume Forecast, by Patient Type
12.1.5.4. Market Revenue and Volume Forecast, by Distribution Channel
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Volume Forecast, by Drug Class
12.1.6.2. Market Revenue and Volume Forecast, by Route of Administration
12.1.6.3. Market Revenue and Volume Forecast, by Patient Type
12.1.6.4. Market Revenue and Volume Forecast, by Distribution Channel
12.2. Europe
12.2.1. Market Revenue and Volume Forecast, by Drug Class
12.2.2. Market Revenue and Volume Forecast, by Route of Administration
12.2.3. Market Revenue and Volume Forecast, by Patient Type
12.2.4. Market Revenue and Volume Forecast, by Distribution Channel
12.2.5. UK
12.2.5.1. Market Revenue and Volume Forecast, by Drug Class
12.2.5.2. Market Revenue and Volume Forecast, by Route of Administration
12.2.5.3. Market Revenue and Volume Forecast, by Patient Type
12.2.5.4. Market Revenue and Volume Forecast, by Distribution Channel
12.2.6. Germany
12.2.6.1. Market Revenue and Volume Forecast, by Drug Class
12.2.6.2. Market Revenue and Volume Forecast, by Route of Administration
12.2.6.3. Market Revenue and Volume Forecast, by Patient Type
12.2.6.4. Market Revenue and Volume Forecast, by Distribution Channel
12.2.7. France
12.2.7.1. Market Revenue and Volume Forecast, by Drug Class
12.2.7.2. Market Revenue and Volume Forecast, by Route of Administration
12.2.7.3. Market Revenue and Volume Forecast, by Patient Type
12.2.7.4. Market Revenue and Volume Forecast, by Distribution Channel
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Volume Forecast, by Drug Class
12.2.8.2. Market Revenue and Volume Forecast, by Route of Administration
12.2.8.3. Market Revenue and Volume Forecast, by Patient Type
12.2.8.4. Market Revenue and Volume Forecast, by Distribution Channel
12.3. APAC
12.3.1. Market Revenue and Volume Forecast, by Drug Class
12.3.2. Market Revenue and Volume Forecast, by Route of Administration
12.3.3. Market Revenue and Volume Forecast, by Patient Type
12.3.4. Market Revenue and Volume Forecast, by Distribution Channel
12.3.5. India
12.3.5.1. Market Revenue and Volume Forecast, by Drug Class
12.3.5.2. Market Revenue and Volume Forecast, by Route of Administration
12.3.5.3. Market Revenue and Volume Forecast, by Patient Type
12.3.5.4. Market Revenue and Volume Forecast, by Distribution Channel
12.3.6. China
12.3.6.1. Market Revenue and Volume Forecast, by Drug Class
12.3.6.2. Market Revenue and Volume Forecast, by Route of Administration
12.3.6.3. Market Revenue and Volume Forecast, by Patient Type
12.3.6.4. Market Revenue and Volume Forecast, by Distribution Channel
12.3.7. Japan
12.3.7.1. Market Revenue and Volume Forecast, by Drug Class
12.3.7.2. Market Revenue and Volume Forecast, by Route of Administration
12.3.7.3. Market Revenue and Volume Forecast, by Patient Type
12.3.7.4. Market Revenue and Volume Forecast, by Distribution Channel
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Volume Forecast, by Drug Class
12.3.8.2. Market Revenue and Volume Forecast, by Route of Administration
12.3.8.3. Market Revenue and Volume Forecast, by Patient Type
12.3.8.4. Market Revenue and Volume Forecast, by Distribution Channel
12.4. MEA
12.4.1. Market Revenue and Volume Forecast, by Drug Class
12.4.2. Market Revenue and Volume Forecast, by Route of Administration
12.4.3. Market Revenue and Volume Forecast, by Patient Type
12.4.4. Market Revenue and Volume Forecast, by Distribution Channel
12.4.5. GCC
12.4.5.1. Market Revenue and Volume Forecast, by Drug Class
12.4.5.2. Market Revenue and Volume Forecast, by Route of Administration
12.4.5.3. Market Revenue and Volume Forecast, by Patient Type
12.4.5.4. Market Revenue and Volume Forecast, by Distribution Channel
12.4.6. North Africa
12.4.6.1. Market Revenue and Volume Forecast, by Drug Class
12.4.6.2. Market Revenue and Volume Forecast, by Route of Administration
12.4.6.3. Market Revenue and Volume Forecast, by Patient Type
12.4.6.4. Market Revenue and Volume Forecast, by Distribution Channel
12.4.7. South Africa
12.4.7.1. Market Revenue and Volume Forecast, by Drug Class
12.4.7.2. Market Revenue and Volume Forecast, by Route of Administration
12.4.7.3. Market Revenue and Volume Forecast, by Patient Type
12.4.7.4. Market Revenue and Volume Forecast, by Distribution Channel
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Volume Forecast, by Drug Class
12.4.8.2. Market Revenue and Volume Forecast, by Route of Administration
12.4.8.3. Market Revenue and Volume Forecast, by Patient Type
12.4.8.4. Market Revenue and Volume Forecast, by Distribution Channel
12.5. Latin America
12.5.1. Market Revenue and Volume Forecast, by Drug Class
12.5.2. Market Revenue and Volume Forecast, by Route of Administration
12.5.3. Market Revenue and Volume Forecast, by Patient Type
12.5.4. Market Revenue and Volume Forecast, by Distribution Channel
12.5.5. Brazil
12.5.5.1. Market Revenue and Volume Forecast, by Drug Class
12.5.5.2. Market Revenue and Volume Forecast, by Route of Administration
12.5.5.3. Market Revenue and Volume Forecast, by Patient Type
12.5.5.4. Market Revenue and Volume Forecast, by Distribution Channel
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Volume Forecast, by Drug Class
12.5.6.2. Market Revenue and Volume Forecast, by Route of Administration
12.5.6.3. Market Revenue and Volume Forecast, by Patient Type
12.5.6.4. Market Revenue and Volume Forecast, by Distribution Channel
13.1. Abbott Laboratories
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial PerDrug Classance
13.1.4. Recent Initiatives
13.2. AbbVie Inc.
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial PerDrug Classance
13.2.4. Recent Initiatives
13.3. Amgen Inc.
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial PerDrug Classance
13.3.4. Recent Initiatives
13.4. Bayer AG
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial PerDrug Classance
13.4.4. Recent Initiatives
13.5. Boehringer Ingelheim
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial PerDrug Classance
13.5.4. Recent Initiatives
13.6. Bristol-Myers Squibb
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial PerDrug Classance
13.6.4. Recent Initiatives
13.7. Celgene Corporation
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial PerDrug Classance
13.7.4. Recent Initiatives
13.8. Eli Lilly and Company
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial PerDrug Classance
13.8.4. Recent Initiatives
13.9. F. Hoffmann-La Roche Ltd.
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial PerDrug Classance
13.9.4. Recent Initiatives
13.10. Galapagos NV
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial PerDrug Classance
13.10.4. Recent Initiatives
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
15.1. About Us
15.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
Plan your call and get expert insights!
Schedule a Meeting
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Get a Sample
Report Description
Get a Sample
Report Description